Dipeptidyl peptidase expression during experimental colitis in mice

Inflammatory Bowel Diseases

Volumn 16, Issue 8, 2010, Pages 1340-1351

  Yazbeck, Roger ^a,b   Sulda, Melanie L ^a   Howarth, Gordon S ^a,b,c   Bleich, Andre ^d   Raber, Kerstin ^e   Von Hörsten, Stephan ^e   Holst, Jens Juul ^f   Abbott, Catherine A ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Animal model; Dextran sulfate sodium; Dipeptidyl peptidase; Glucagon like peptide; Inflammatory bowel disease; Neutrophils; Regulatory T cell

Indexed keywords

DEXTRAN SULFATE; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRINKING WATER; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; MESSENGER RNA; MYELOPEROXIDASE; SODIUM CHLORIDE; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; ENZYME ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HISTOPATHOLOGY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; REGULATORY T LYMPHOCYTE; STOMACH PROTECTION; T LYMPHOCYTE; WILD TYPE;

ANIMALS; COLITIS; COLON; DEXTRAN SULFATE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; PEROXIDASE; T-LYMPHOCYTES, REGULATORY;

EID: 77955761398     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21241     Document Type: Article

References (58)

1. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond). 2005;108:277-292.
2. Durinx C, Lambeir AM, Bosmans E, et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem. 2000;267:5608-5613.
3. Bergmann A, Bohuon C. Decrease of serum dipeptidylpeptidase activity in severe sepsis patients: relationship to procalcitonin. Clin Chim Acta. 2002;321:123-126. (Pubitemid 34597061)
4. Drucker DJ, Shi Q, Crivici A, et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. 1997;15:673-677. (Pubitemid 27291170)
5. Yazbeck R, Howarth GS, Abbott CA. Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward? Cytokine Growth Factor Rev. 2009;20:175-184.
6. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev. 1998;161:55-70. (Pubitemid 28119018)
7. Aytac U, Dang NH. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4:11-18. (Pubitemid 38854877)
8. Preller V, Gerber A, Togni M, et al. CD26/DP IV in T cell activation and autoimmunity. Adv Exp Med Biol. 2006;575:187-193.
9. Cordero OJ, Yang CP, Bell EB. On the role of CD26 in CD4 memory T cells. Immunobiology. 2007;212:85-94. (Pubitemid 46317353)
10. Abbott CA, McCaughan GW, Levy MT, et al. Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain. Eur J Biochem. 1999;266:798-810.
11. Vukmanovic-Stejic M, Zhang Y, Cook JE, et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest. 2006;116:2423-2433.
12. Skripuletz T, Schmiedl A, Schade J, et al. Dose-dependent recruitment of CD25+ and CD26+ T cells in a novel F344 rat model of asthma. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1564-1571. (Pubitemid 47077372)
13. Schade J, Stephan M, Schmiedl A, et al. Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. J Histochem Cytochem. 2008;56:147-155. (Pubitemid 351170967)
14. Abbott CA, Yu DM, Woollatt E, et al. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem. 2000;267:6140-6150.
15. Ajami K, Abbott CA, McCaughan GW, et al. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta. 2004;1679: 18-28. (Pubitemid 38881620)
16. Ajami K, Pitman MR, Wilson CH, et al. Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett. 2008;582:819-825.
17. Maes MB, Dubois V, Brandt I, et al. Dipeptidyl peptidase 8/9-like activity in human leukocytes. J Leukoc Biol. 2007;81:1252-1257. (Pubitemid 46702044)
18. Pitman MR, Sulda ML, Kuss B, et al. Dipeptidyl peptidase 8 and 9 - guilty by association? Front Biosci. 2009;14:3619-3633.
19. Maes MB, Lambeir AM, Gilany K, et al. Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). Biochem J. 2005;386:315-324. (Pubitemid 40343789)
20. Gotoh H, Hagihara M, Nagatsu T, et al. Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin Chem. 1989;35:1016-1018. (Pubitemid 19161276)
21. Mentlein R, Struckhoff G. Purification of two dipeptidyl aminopeptidases II from rat brain and their action on proline-containing neuropeptides. J Neurochem. 1989;52:1284-1293. (Pubitemid 19085956)
22. Cox SW, Gazi MI, Eley BM. Dipeptidyl peptidase II- and IV-like activities in gingival tissue and crevicular fluid from human periodontitis lesions. Arch Oral Biol. 1992;37:167-173.
23. Maes MB, Scharpe S, De Meester I. Dipeptidyl peptidase II (DPPII), a review. Clin Chim Acta. 2007;380:31-49.
24. Yazbeck R, Howarth GS, Geier MS, et al. Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. Front Biosci. 2008;13:6850-6858.
25. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA. 2000;97:6874-6879. (Pubitemid 30412807)
26. Murthy SN, Cooper HS, Shim H, et al. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 1993;38:1722-1734. (Pubitemid 23271431)
27. Howarth GS, Xian CJ, Read LC. Predisposition to colonic dysplasia is unaffected by continuous administration of insulin-like growth factor-I for twenty weeks in a rat model of chronic inflammatory bowel disease. Growth Factors. 2000;18:119-133.
28. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52:741-750. (Pubitemid 36323582)
29. Frerker N, Wagner L, Wolf R, et al. Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4. Peptides. 2007;28:257-268. (Pubitemid 46188365)
30. Hartmann B, Thulesen J, Kissow H, et al. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology. 2000;141:4013-4020.
31. Orskov C, Holst JJ. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest. 1987;47:165-174. (Pubitemid 17050199)
32. Yin JL, Shackel NA, Zekry A, et al. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I. Immunol Cell Biol. 2001;79:213-221. (Pubitemid 32522168)
33. Beyer AJ, Smalley DM, Shyr YM, et al. PAF and CD18 mediate neutrophil infiltration in upper gastrointestinal tract during intra-abdominal sepsis. Am J Physiol. 1998;275:G467-472.
34. Geier MS, Tenikoff D, Yazbeck R, et al. Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. J Cell Physiol. 2005;204:687-692. (Pubitemid 40934665)
35. Ansorge S, Bank U, Heimburg A, et al. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47:253-261.
36. Yu DM, Ajami K, Gall MG, et al. The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem. 2009;57:1025-1040.
37. De Meester I, Korom S, Van Damme J, et al. CD26, let it cut or cut it down. Immunol Today. 1999;20:367-375.
38. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors an emerging drug class for inflammatory disease? Trends Pharmacol Sci. 2009;30:600-607.
39. Reinhold D, Bank U, Buhling F, et al. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology. 1997;91:354-360. (Pubitemid 27304270)
40. Reinhold D, Bank U, Buhling F, et al. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes. Immunol Lett. 1997;58:29-35. (Pubitemid 27232383)
41. Preller V, Gerber A, Wrenger S, et al. TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol. 2007;178:4632-4640. (Pubitemid 46492416)
42. Busso N, Wagtmann N, Herling C, et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol. 2005;166:433-442. (Pubitemid 40189040)
43. Fan H, Yan S, Stehling S, et al. Dipeptidyl peptidase IV/CD26 in T cell activation, cytokine secretion and immunoglobulin production. Adv Exp Med Biol. 2003;524:165-174. (Pubitemid 36570823)
44. Klemann C, Schade J, Pabst R, et al. CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently. Clin Exp Immunol. 2009;155:357-365.
45. Kim SJ, Nian C, Doudet DJ, et al. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes. 2009;58:641-651.
46. Williams IR, Parkos CA. Colonic neutrophils in inflammatory bowel disease: double-edged swords of the innate immune system with protective and destructive capacity. Gastroenterology. 2007;133:2049-2052.
47. Naito Y, Takagi T, Yoshikawa T. Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease. J Gastroenterol. 2007;42:787-798. (Pubitemid 47617456)
48. Stevceva L, Pavli P, Husband AJ, et al. The inflammatory infiltrate in the acute stage of the dextran sulphate sodium induced colitis: B cell response differs depending on the percentage of DSS used to induce it. BMC Clin Pathol. 2001;1:3.
49. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006;212:256-271. (Pubitemid 44116713)
50. Bank U, Heimburg A, Helmuth M, et al. Triggering endogenous immunosuppressive mechanisms by combined targeting of dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/ CD13) - a novel approach for the treatment of inflammatory bowel disease. Int Immunopharmacol. 2006;6:1925-1934. (Pubitemid 44855708)
51. Orskov C, Holst JJ, Knuhtsen S, et al. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 1986;119:1467-1475. (Pubitemid 17170509)
52. Drucker DJ, DeForest L, Brubaker PL. Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am J Physiol. 1997;273:G1252-1262.
53. Burrin DG, Stoll B, Guan X, et al. Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology. 2005;146:22-32. (Pubitemid 40051718)
54. Pereira-Fantini PM, Nagy ES, Thomas SL, et al. GLP-2 administration results in increased proliferation but paradoxically an adverse outcome in a juvenile piglet model of short bowel syndrome. J Pediatr Gastroenterol Nutr. 2008;46:20-28.
55. Drucker DJ, Yusta B, Boushey RP, et al. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol. 1999;276:G79-91.
56. Alavi K, Schwartz MZ, Palazzo JP, et al. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg. 2000;35:847-851. (Pubitemid 30346176)
57. Orskov C, Hartmann B, Poulsen SS, et al. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept. 2005;124:105-112. (Pubitemid 39488347)
58. Dube PE, Forse CL, Bahrami J, et al. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology. 2006;131:589-605. (Pubitemid 44142460)